| Symbol | ACXP |
|---|---|
| Name | ACURX PHARMACEUTICALS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 259 LIBERTY AVE, STATEN ISLAND, New York, 10305, United States |
| Telephone | +1 917 533-1469 |
| Fax | — |
| — | |
| Website | https://www.acurxpharma.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | — |
| Description | Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. Additional info from NASDAQ: |
Director Sailer Carl 🟢 acquired 2.1K shares (1 derivative) of Acurx Pharmaceuticals, Inc. (ACXP) at $2.36 Transaction Date: Apr 20, 2026 | Filing ID: 046846
Read moreDirector DEAN JACK H 🟢 acquired 2.1K shares (1 derivative) of Acurx Pharmaceuticals, Inc. (ACXP) at $2.36 Transaction Date: Apr 20, 2026 | Filing ID: 046844
Read moreDirector Donohue James J. 🟢 acquired 2.1K shares (1 derivative) of Acurx Pharmaceuticals, Inc. (ACXP) at $2.36 Transaction Date: Apr 20, 2026 | Filing ID: 046842
Read moreDirector HARRISON THOMAS L 🟢 acquired 2.1K shares (1 derivative) of Acurx Pharmaceuticals, Inc. (ACXP) at $2.36 Transaction Date: Apr 20, 2026 | Filing ID: 046840
Read moreDirector Scodari Joseph C 🟢 acquired 2.1K shares (1 derivative) of Acurx Pharmaceuticals, Inc. (ACXP) at $2.36 Transaction Date: Apr 20, 2026 | Filing ID: 046837
Read moreDirector DELUCCIA ROBERT J 🟢 acquired 37.1K shares (1 derivative) of Acurx Pharmaceuticals, Inc. (ACXP) at $2.36 Transaction Date: Apr 20, 2026 | Filing ID: 046836
Read moreDirector LUCI DAVID P 🟢 acquired 37.1K shares (1 derivative) of Acurx Pharmaceuticals, Inc. (ACXP) at $2.36 Transaction Date: Apr 20, 2026 | Filing ID: 046835
Read moreShawah Robert G. 🟢 acquired 25.9K shares (1 derivative) of Acurx Pharmaceuticals, Inc. (ACXP) at $2.36 Transaction Date: Apr 20, 2026 | Filing ID: 046833
Read moreAcurx Pharmaceuticals to Discuss First Quarter 2026 Financial Results on May 12, 2026 Conference Call and Provide Business Update
Read more(99% Neutral) ACURX PHARMACEUTICALS, INC. (ACXP) Announces Clinical Development Update
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07513285 | ACX-362E [Ibezapolstat] for Oral Treatment of Recurrent Clostridioides Difficil… | Phase2 | Clostridium Difficile Infection Recurrence | Not_Yet_Recruiting | 2026-08-19 | 2027-11-24 | ClinicalTrials.gov |
| NCT04247542 | ACX-362E [Ibezapolstat] for Oral Treatment of Clostridioides Difficile Infection | Phase2 | Clostridium Difficile Infection | Completed | 2020-03-06 | 2023-11-15 | ClinicalTrials.gov |
| NCT02291861 | Addressing Involuntary Movements in Tardive Dyskinesia | Phase3 | Tardive Dyskinesia | Completed | 2014-10-31 | 2016-08-19 | ClinicalTrials.gov |
| NCT02198794 | Reducing Involuntary Movements in Participants With Tardive Dyskinesia | Phase3 | Tardive Dyskinesia | Completed | 2014-10-20 | 2020-12-14 | ClinicalTrials.gov |
| NCT02674321 | A Pilot Study Of SD-809 (Deutetrabenazine) In Moderate To Severe Tourette Syndr… | Phase1 | TOURETTE SYNDROME | Completed | 2014-07-01 | 2015-06-01 | ClinicalTrials.gov |
| NCT02195700 | Aim to Reduce Movements in Tardive Dyskinesia | Phase2 | Tardive Dyskinesia | Completed | 2014-06-01 | 2015-05-01 | ClinicalTrials.gov |
| NCT01897896 | Alternatives for Reducing Chorea in Huntington Disease | Phase3 | Chorea Associated With Huntington Disease | Completed | 2013-11-12 | 2017-08-21 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo | DRUG | Phase PHASE3 | Tardive Dyskinesia | COMPLETED | NCT02291861 |
| SD-809 | DRUG | Phase PHASE1 | TOURETTE SYNDROME | COMPLETED | NCT02674321 |
| Vancomycin | DRUG | Phase PHASE2 | Clostridium Difficile Infection | COMPLETED | NCT04247542 |
| Ibezapolstat | DRUG | Phase PHASE2 | Clostridium Difficile Infection Recurrence | NOT_YET_RECRUITING | NCT07513285 |